The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).
 
Roberto Ferrara
No Relationships to Disclose
 
Laura Mezquita
No Relationships to Disclose
 
Matthieu Texier
No Relationships to Disclose
 
Jihene Lahmar
No Relationships to Disclose
 
Clarisse Audigier-Valette
No Relationships to Disclose
 
Laurent Tessonnier
No Relationships to Disclose
 
Julien Mazieres
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly/ImClone; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Pfizer; Roche
 
Solenn Brosseau
No Relationships to Disclose
 
Laura Leroy
No Relationships to Disclose
 
Boris Duchemann
No Relationships to Disclose
 
Corentin Lefebvre
No Relationships to Disclose
 
Remi Veillon
Consulting or Advisory Role - MSD Oncology; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology; Roche
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Merck KGaA (Inst); Roche (Inst); Takeda (Inst)
 
Virginie Westeel
No Relationships to Disclose
 
Stephane Champiat
No Relationships to Disclose
 
David Planchard
Honoraria - PeerVoice; Prime Oncology
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MedImmune; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst)
 
Jordi Remon
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer
Travel, Accommodations, Expenses - Inivata; OSE Immunotherapeutics; OSE Immunotherapeutics; Roche/Genentech
 
Anas Gazzah
No Relationships to Disclose
 
Jean-Charles Soria
Honoraria - AstraZeneca/MedImmune; Merus; MSD Oncology; Pfizer; Roche; Symphogen
 
Caroline Caramella
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Biogen (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Inivata (Inst); Ipsen (Inst); Lilly (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Onxeo (Inst); Pfizer (Inst); PharmaMar (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); Tiziana Therapeutics (Inst)